AI Engines For more Details: Perplexity Kagi Labs You
Cancer Treatment: Cyclophosphamide is used in the treatment of various types of cancer, including leukemia, lymphoma, multiple myeloma, breast cancer, ovarian cancer, and lung cancer, among others. It is often used in combination with other chemotherapy drugs or as part of multi-agent chemotherapy regimens. Cyclophosphamide works by interfering with the growth and replication of cancer cells, leading to their destruction. It is particularly effective against rapidly dividing cancer cells.
Allogeneic Stem Cell Transplantation: Cyclophosphamide is also used in the conditioning regimen for allogeneic stem cell transplantation (also known as bone marrow transplantation). In this setting, cyclophosphamide is given at high doses to suppress the recipient's immune system and prevent rejection of the transplanted stem cells. This allows for engraftment of donor stem cells and reconstitution of the recipient's immune system.
Autoimmune Diseases: In addition to its use as a cancer treatment, cyclophosphamide is used in the management of certain autoimmune diseases and immune-mediated disorders. It may be used in conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), and other autoimmune vasculitides. Cyclophosphamide works by suppressing the abnormal immune response that leads to tissue damage and inflammation in these conditions.
Nephrotic Syndrome: Cyclophosphamide may be used in the treatment of nephrotic syndrome, a kidney disorder characterized by proteinuria (excessive protein in the urine), hypoalbuminemia (low levels of albumin in the blood), edema (swelling), and hyperlipidemia (high cholesterol levels). It is particularly used in cases of steroid-resistant or steroid-dependent nephrotic syndrome to induce remission and reduce proteinuria.
Dosage and Administration: Cyclophosphamide is typically administered orally in the form of tablets or intravenously (IV) as a solution for injection. The dosage and duration of treatment depend on factors such as the type of cancer or medical condition being treated, the patient's overall health, and their response to therapy. Cyclophosphamide is often given in cycles, with rest periods between doses to allow the body to recover from side effects.
Side Effects: Common side effects of cyclophosphamide may include nausea, vomiting, diarrhea, hair loss (alopecia), myelosuppression (decreased production of blood cells), increased risk of infection, mucositis (inflammation of the mucous membranes), and infertility. Long-term use of cyclophosphamide may be associated with an increased risk of certain malignancies, particularly bladder cancer. Patients should be monitored regularly for side effects during cyclophosphamide therapy, and treatment should be adjusted as needed based on individual response and tolerance.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.6 | 0.3 | 1 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
| Allergies | 0.2 | 0.9 | -3.5 |
| Allergy to milk products | 0.3 | 0.1 | 2 |
| Alzheimer's disease | 0.5 | 1.6 | -2.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.2 | 1.5 |
| Ankylosing spondylitis | 1.2 | 0.5 | 1.4 |
| Anorexia Nervosa | 0.4 | -0.4 | |
| Antiphospholipid syndrome (APS) | 1 | 0.2 | 4 |
| Asthma | 0 | 0.4 | 0 |
| Atherosclerosis | 0 | 1.2 | 0 |
| Atrial fibrillation | 0.3 | 1.2 | -3 |
| Autism | 3.2 | 2 | 0.6 |
| Barrett esophagus cancer | 0 | 0 | |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.3 | 0.6 | -1 |
| Brain Trauma | 0.4 | -0.4 | |
| Carcinoma | 0.4 | 0.1 | 3 |
| Celiac Disease | 0.5 | 0.3 | 0.67 |
| Cerebral Palsy | 0.4 | -0.4 | |
| Chronic Fatigue Syndrome | 1.2 | 1.2 | 0 |
| Chronic Kidney Disease | 1.2 | 0.6 | 1 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.6 | 0 |
| Chronic Urticaria (Hives) | 0.3 | 0.9 | -2 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.4 | -0.33 |
| Colorectal Cancer | 0.9 | 0.9 | |
| Constipation | 0.3 | 0.4 | -0.33 |
| Coronary artery disease | 0.4 | 0.3 | 0.33 |
| COVID-19 | 0.7 | 2.8 | -3 |
| Crohn's Disease | 2 | 0.8 | 1.5 |
| cystic fibrosis | 0.3 | 0.4 | -0.33 |
| deep vein thrombosis | 0.3 | 0.4 | -0.33 |
| Depression | 1.8 | 1.8 | 0 |
| Eczema | 0.6 | 0.6 | |
| Endometriosis | 0.7 | 0.1 | 6 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.2 | 0 | 0 |
| Fibromyalgia | 0.4 | 1.6 | -3 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 2.1 | -0.62 |
| gallstone disease (gsd) | 0.1 | 0.4 | -3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
| Generalized anxiety disorder | 0.8 | 0.3 | 1.67 |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0 | 0.4 | 0 |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 1 | 0.2 | 4 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.3 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.1 | 0 | 0 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.2 | 0.9 | -3.5 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0 | 0 | |
| IgA nephropathy (IgAN) | 1.5 | -1.5 | |
| Inflammatory Bowel Disease | 0.8 | 2.2 | -1.75 |
| Insomnia | 0 | 0.4 | 0 |
| Intelligence | 0.4 | 0.9 | -1.25 |
| Intracranial aneurysms | 0 | 0 | |
| Irritable Bowel Syndrome | 0.8 | 0.7 | 0.14 |
| Liver Cirrhosis | 1.1 | 0.8 | 0.38 |
| Long COVID | 1.7 | 1 | 0.7 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.2 | 0.6 | -2 |
| ME/CFS without IBS | 0.6 | 0 | 0 |
| Metabolic Syndrome | 1.8 | 1.2 | 0.5 |
| Mood Disorders | 2.2 | 1.8 | 0.22 |
| Multiple Sclerosis | 0.2 | 1.3 | -5.5 |
| Neuropathy (all types) | 0.1 | -0.1 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 0.4 | 1.5 |
| Obesity | 2.1 | 0.9 | 1.33 |
| obsessive-compulsive disorder | 0.7 | 2.3 | -2.29 |
| Osteoarthritis | 0.6 | 0.6 | |
| Osteoporosis | 0.2 | 0 | 0 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.7 | 1.5 | -1.14 |
| Polycystic ovary syndrome | 0.3 | 0.4 | -0.33 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 0.2 | 1.5 | -6.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 0.8 | 1.87 |
| Rosacea | 0.6 | 0.4 | 0.5 |
| Schizophrenia | 0.7 | 0.6 | 0.17 |
| scoliosis | 0.3 | 0.2 | 0.5 |
| Sjögren syndrome | 1.1 | 0.2 | 4.5 |
| Sleep Apnea | 0.3 | 0.7 | -1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.7 | 0.7 | 0 |
| Systemic Lupus Erythematosus | 1.2 | 0.4 | 2 |
| Tic Disorder | 0.3 | 0.9 | -2 |
| Tourette syndrome | 0 | 0 | |
| Type 1 Diabetes | 0.8 | 0.5 | 0.6 |
| Type 2 Diabetes | 1.9 | 1.3 | 0.46 |
| Ulcerative colitis | 0.6 | 2.1 | -2.5 |
| Unhealthy Ageing | 2 | 0.7 | 1.86 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.